Void Where Prohibited

Breakthroughs in Atopic Dermatitis with Linda Stein Gold, MD: Primary Viewpoints Podcast

Approximately one-third of participants treated with rocatinlimab achieved EASI-75 at 24 weeks, more than 2 times the proportion in the placebo group, among other robust findings.

Linda Stein Gold, MD;Sydney Jennings

Dupilumab Demonstrates Superior Long-Term Persistence Over Upadacitinib and Tralokinumab in Atopic Dermatitis

“I think it’s important to have a lot of tools in our toolbox, and [tapinarof cream 1%] is one that gives us great flexibility," said Linda Stein Gold, MD.

Primary Viewpoints: Immunizations with Dr Steven P. Furr

Dupilumab was associated with the highest drug survival in monotherapy with nearly 90% of study participants remaining on treatment at both 12 and 24 months.

Keith A. Reynolds

October 1st 2024

Ruxolitinib Cream 1.5% Demonstrates Efficacy in Prurigo Nodularis: Phase 3 Findings

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Steven P. Furr, former president of the American Academy of Family Physicians.

Patient Care Editorial Staff

Rocatinlimab Shows Significant Efficacy in Moderate to Severe Atopic Dermatitis: Phase 3 IGNITE Trial Results

Data from the TRuE-PN trial program were presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting in Orlando, offering important insights into potential new therapeutic options for this debilitating condition.

Rocatinlimab, an OX40 Inhibitor, Achieves Positive Results in Atopic Dermatitis Treatment: ROCKET-Horizon Topline Findings

AAD 2025: The IGNITE study of the OX40 inhibitor included adults previously treated with a biologic or systemic JAK inhibitor, according to Amgen and Kyowa Kirin.

Related Content

Breakthroughs in Atopic Dermatitis with Linda Stein Gold, MD: Primary Viewpoints Podcast

Approximately one-third of participants treated with rocatinlimab achieved EASI-75 at 24 weeks, more than 2 times the proportion in the placebo group, among other robust findings.

Linda Stein Gold, MD;Sydney Jennings

Dupilumab Demonstrates Superior Long-Term Persistence Over Upadacitinib and Tralokinumab in Atopic Dermatitis

“I think it’s important to have a lot of tools in our toolbox, and [tapinarof cream 1%] is one that gives us great flexibility," said Linda Stein Gold, MD.

Primary Viewpoints: Immunizations with Dr Steven P. Furr

Dupilumab was associated with the highest drug survival in monotherapy with nearly 90% of study participants remaining on treatment at both 12 and 24 months.

Keith A. Reynolds

October 1st 2024

Ruxolitinib Cream 1.5% Demonstrates Efficacy in Prurigo Nodularis: Phase 3 Findings

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Steven P. Furr, former president of the American Academy of Family Physicians.

Patient Care Editorial Staff

Rocatinlimab Shows Significant Efficacy in Moderate to Severe Atopic Dermatitis: Phase 3 IGNITE Trial Results